TY - CHAP A1 - Julio C. Torres-Romero A2 - Julio César Lara-Riegos A3 - Edgar Antonio Estrella Parra A4 - Verónica Fernández Sánchez A5 - Victor E. Arana-Argáez A6 - Sushally Uc-Colli A7 - Miguel Ángel Peña-Rico A8 - Mario Alberto Ramírez-Camacho A9 - Maria Dolores Ponce Regalado A10 - María Elizbeth Alvarez-Sánchez ED1 - Arli Aditya Parikesit Y1 - 2021-06-16 PY - 2021 T1 - Lipoproteomics: Methodologies and Analysis of Lipoprotein-Associated Proteins along with the Drug Intervention N2 - Right before the COVID-19 pandemic declared by the World Health Organization (WHO), life sciences have incited novel areas of studies that revolutionize the health sector. They are the studies of structural bioinformatics, pharmacogenomics, and metabolomics. The structural bioinformatics field is the very foundation of drug design research, as it provides insight into the molecular simulations and interactions between the biomolecules and the drug candidates. Secondly, pharmacogenomics is the starting point of any efforts in developing personalized medicine. Lastly, metabolomics provides instrumentation to elicit biomarkers for various diseases and health conditions. These studies have enabled current accelerated effort in COVID-19 research, as well as other communicable and non-communicable diseases. BT - Drug Design SP - Ch. 3 UR - https://doi.org/10.5772/intechopen.93634 DO - 10.5772/intechopen.93634 SN - 978-1-78984-753-6 PB - IntechOpen CY - Rijeka Y2 - 2021-10-17 ER -